A consortium led by Yunfeng Capital and Chinese biopharmaceutical company Hybio Pharmaceutical has entered into an agreement to buy all the shares of German speciality pharmaceutical firm AMW GmbH.
AMW GmbH is a specialty pharmaceuticals company headquartered in Warngau near Munich, Germany. It develops, produces and sells drug delivery systems with a focus on biodegradable implants and transdermal treatment systems. The company was founded in 2008 and develops solutions for use in oncology, neurology, dermatology and pain management applications.
Shenzhen-based Hybio is a Chinese biopharmaceutical company that focuses on research, development, manufacturing and commercialization of peptides and peptide-based drugs.
The new owners are following an international expansion strategy-adding products and a R&D pipeline to the portfolio. Synergies include the use of a global sales force, especially in the key markets of the USA and China, as well as the start of new development projects, AMW said.